SAN DIEGO, July 2, 2025 /PRNewswire/ -- A new prospective study published in BMC Cancer demonstrates that a novel blood-based multi-omics test, SeekInClarity, can accurately...
Award is one of Houston’s most inspiring celebrations of leadership, where CEOs and visionaries are at the helm of the city’s most successful and impactful organizations
Award is one of Houston’s most inspiring celebrations of leadership, where CEOs and visionaries are at the helm of the city’s most successful and impactful organizations
Equity Insider News Commentary
Issued on behalf of Avant Technologies Inc.
VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- Several experts are seeing that value of AI's total overhaul...
Financing to accelerate commercialization of flagship products, service business, and entrance into U.S. market
STOCKHOLM, June 30, 2025 /PRNewswire/ -- Epigenica AB, a pioneer in high-throughput...
In the study of rare diseases and precision medicine, understanding gene expression in the spatial context of tissues is essential. High-throughput sequencing and STOmics technology will...
BOSTON, June 25, 2025 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting...
The role of American universities in driving entrepreneurial success is indisputable, particularly in their contribution to foundational technologies and medical advancements. This direct link...
Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach
Positions Illumina to achieve growth in a large, expanding market
Illumina and...
BOSTON, June 24, 2025 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced the appointment of Murray...
In a landmark advancement for women's cancer research, Dr. Takuma Hayashi and his team have made groundbreaking discoveries that could transform our understanding and...
Lilly Collaboration Accelerates RyboDyn's Dark Proteome Targets Toward First-in-Class Therapies
SAN DIEGO, June 19, 2025 /PRNewswire/ -- RyboDyn, Inc., a biotechnology company pioneering first-in-class immunotherapies...